LEAP (Liver Education & Action Program) at Mount Sinai aims to improve the treatment of hepatitis C (HCV) infection in NYC. It is estimated that 146,500 NYC adults (2.4% of the NYC population) have chronic HCV infection, which causes cirrhosis, end-stage liver disease, liver cancer, and death in 20% of infected persons. LEAP utilizes comprehensive care coordination to assist medical providers in improving overall outcomes related to treatment while reducing psychosocial and behavioral barriers to care.
LEAP (Liver Education & Action Program) at Mount Sinai aims to improve the treatment of hepatitis C (HCV) infection in NYC. It is estimated that 146,500 NYC adults (2.4% of the NYC population) have chronic HCV infection, which causes cirrhosis…